Warfarin time in therapeutic range and its impact on healthcare resource utilization and costs among patients with nonvalvular atrial fibrillation

References

• Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) study. JAMA 2001;285:2370-5
   PubMed Web of Science ®Google Scholar
• Naccarelli GV, Varker H, Lin J, Schulman KL. Increasing prevalence of atrial fibrillation and flutter in the United States. Am J Cardiol 2009;104:1534-9
   PubMed Web of Science ®Google Scholar
• Kim MH, Lin J, Hussein M, et al. Cost of atrial fibrillation in United States managed care organizations. Adv Ther 2009;26:847-57
   PubMed Web of Science ®Google Scholar
• Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007;146:857-67
   PubMed Web of Science ®Google Scholar
• Singer DE, Albers GW, Dalen JE, et al. American College of Chest Physicians. Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008;133:546-92S
   PubMed Web of Science ®Google Scholar
• Razouki Z, Ozonoff A, Zhao S, et al. Improving quality measurement for anticoagulation: adding international normalized ratio variability to percent time in therapeutic range. Circ Cardiovasc Qual Outcomes 2014;7:664-9
   PubMed Web of Science ®Google Scholar
• Rosendaal FR, Cannegieter SC, van der Meer FJ, Briët E. A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost 1993;69:236-9
   PubMed Web of Science ®Google Scholar
• Kim YK, Nieuwlaat R, Connolly SJ, et al. Effect of a simple two-step warfarin dosing algorithm on anticoagulant control as measured by time in therapeutic range: a pilot study. J Thromb Haemost 2010;8:101-6
   PubMed Web of Science ®Google Scholar
• Cancino RS, Hylek EM, Reisman JI, Rose AJ. Comparing patient-level and site-level anticoagulation control as predictors of adverse events. Thromb Res 2014;133:652-6
   PubMed Web of Science ®Google Scholar
• Mueller S, Pfannkuche M, Breithardt G, et al. The quality of oral anticoagulation in general practice in patients with atrial fibrillation. Eur J Intern Med 2014;25:247-54
   PubMed Web of Science ®Google Scholar
• Consumer Price Index December 2013. USDL-14-0037. Bureau of Labor Statistics US Department of Labor. Washington DC. Available at: http://www.bls.gov/news.release/archives/cpi_01162014.pdf. [Last Accessed 4 November 2014]
   Google Scholar
• An J, Lang D, Jazdzewski K, et al. Antithrombotic treatment patterns among newly diagnosed non-valvular atrial fibrillation patients. Paper presented at: The International Stroke Conference, 12–14 February 2014, San Diego, CA, USA
   Google Scholar
• Baker WL, Cios DA, Sander SD, Coleman CI. Meta-analysis to assess the quality of warfarin control in atrial fibrillation patients in the United States. J Manag Care Pharm 2009;15:244-52
   PubMed Web of Science ®Google Scholar
• Mearns ES, White CM, Kohn CG, et al. Quality of vitamin K antagonist control and outcomes in atrial fibrillation patients: a meta-analysis and meta-regression. Thromb J 2014;12:14
   PubMedGoogle Scholar
• Dlott JS, George RA, Huang X, et al. National assessment of warfarin anticoagulation therapy for stroke prevention in atrial fibrillation. Circulation 2014;129:1407-14
   PubMed Web of Science ®Google Scholar
• Cryder B, Felczak M, Janociak J, et al. Prevalent aetiologies of non-therapeutic warfarin anticoagulation in a network of pharmacist-managed anticoagulation clinics. J Clin Pharm Ther 2011;36:64-70
   PubMed Web of Science ®Google Scholar
• Rose AJ, Hylek EM, Ozonoff A, et al. Patient characteristics associated with oral anticoagulation control: results of the Veterans AffaiRs Study to Improve Anticoagulation (VARIA). J Thromb Haemost 2010;8:2182-91
   PubMed Web of Science ®Google Scholar
• Nelson WW, Choi JC, Vanderpoel J, et al. Impact of co-morbidities and patient characteristics on international normalized ratio control over time in patients with nonvalvular atrial fibrillation. Am J Cardiol 2013;112:509-12
   PubMed Web of Science ®Google Scholar
• Connolly SJ, Pogue J, Eikelboom J, et al. ACTIVE W Investigators. Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range. Circulation 2008;118:2029-37
   PubMed Web of Science ®Google Scholar
• Morgan CL, McEwan P, Tukiendorf A, et al. Warfarin treatment in patients with atrial fibrillation: observing outcomes associated with varying levels of INR control. Thromb Res 2009;124:37-41
   PubMed Web of Science ®Google Scholar
• White HD, Gruber M, Feyzi J, et al. Comparison of outcomes among patients randomized to warfarin therapy according to anticoagulant control: results from SPORTIF III and V. Arch Intern Med 2007;167:239-45
   PubMed Web of Science ®Google Scholar
• Wallentin L, Yusuf S, Ezekowitz MD, et al. RE-LY Investigators. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. Lancet 2010;376:975-83
   PubMed Web of Science ®Google Scholar
• Hall D, Buchanan J, Helms B, et al. Health care expenditures and therapeutic outcomes of a pharmacist-managed anticoagulation service versus usual medical care. Pharmacotherapy 2011;31:686-94
   PubMed Web of Science ®Google Scholar
• Lesén E, Björholt I, Björstad A, et al. Impact of short periods with worsened or improved INR control on life expectancy and QALYs in patients with atrial fibrillation. Thromb Res 2014;133:1061-7
   PubMed Web of Science ®Google Scholar
• Rudd KM, Dier JG. Comparison of two different models of anticoagulation management services with usual medical care. Pharmacotherapy 2010;30:330-8
   PubMed Web of Science ®Google Scholar
• Hylek EM. Vitamin K antagonists and time in the therapeutic range: implications, challenges, and strategies for improvement. J Thromb Thrombolysis 2013;35:333-5
   PubMed Web of Science ®Google Scholar